Lyell Immunopharma, Inc. (LYEL)
NASDAQ: LYEL · Real-Time Price · USD
0.3988
+0.0088 (2.26%)
May 15, 2025, 3:39 PM - Market open
Lyell Immunopharma Revenue
Lyell Immunopharma had revenue of $7.00K in the quarter ending March 31, 2025, with 133.33% growth. This brings the company's revenue in the last twelve months to $65.00K, down -4.41% year-over-year. In the year 2024, Lyell Immunopharma had annual revenue of $61.00K, down -53.08%.
Revenue (ttm)
$65.00K
Revenue Growth
-4.41%
P/S Ratio
1,772.03
Revenue / Employee
$217
Employees
300
Market Cap
117.78M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
LYEL News
- 1 day ago - Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2025 - GlobeNewsWire
- 14 days ago - Lyell Immunopharma Announces Oral Presentation of New Clinical Data from the Phase 1/2 Trial of LYL314 for the Treatment of Large B-cell Lymphoma at the International Conference on Malignant Lymphoma (ICML) 2025 - GlobeNewsWire
- 4 weeks ago - Lyell Immunopharma Receives Regenerative Medicine Advanced Therapy (RMAT) Designation for LYL314 for the Treatment of Relapsed and/or Refractory Large B-Cell Lymphoma - GlobeNewsWire
- 2 months ago - Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2024 - GlobeNewsWire
- 3 months ago - Lyell Immunopharma Announces Participation in Upcoming Investor Conferences - GlobeNewsWire
- 4 months ago - Lyell to Highlight Vision for its Next-Generation CAR T-Cell Therapy Pipeline at 43rd Annual JP Morgan Healthcare Conference - GlobeNewsWire
- 5 months ago - Lyell Presents Positive Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the Treatment of B-cell Lymphoma at the 2024 ASH Annual Meeting - GlobeNewsWire
- 6 months ago - Lyell Announces Presentation of Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the treatment of B-cell Lymphoma at the 2024 American Society of Hematology (ASH) Annual Meeting - GlobeNewsWire